Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG099
MIFTS: 70

Lung Disease

Categories: Blood diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lung Disease

About this section

MalaCards integrated aliases for Lung Disease:

Name: Lung Disease 12 15 17
Lung Diseases 56 44 45 74
Disorder of Lung 30

Classifications:

MalaCards categories:
Anatomical: Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:850
MeSH 45 D008171
NCIt 51 C3198
SNOMED-CT 69 19829001
ICD10 34 J60-J70 J98.4
UMLS 74 C0024115
Sources

Summaries for Lung Disease

About this section
MedlinePlus : 44 When you breathe, your lungs take in oxygen from the air and deliver it to the bloodstream. The cells in your body need oxygen to work and grow. During a normal day, you breathe nearly 25,000 times. People with lung disease have difficulty breathing. Millions of people in the U.S. have lung disease. If all types of lung disease are lumped together, it is the number three killer in the United States. The term lung disease refers to many disorders affecting the lungs, such as asthma, COPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure. Dept. of Health and Human Services Office on Women's Health

MalaCards based summary : Lung Disease, also known as lung diseases, is related to interstitial lung disease and pulmonary disease, chronic obstructive, and has symptoms including dyspnea, apnea and hemoptysis. An important gene associated with Lung Disease is SFTPC (Surfactant Protein C), and among its related pathways/superpathways are Metabolism of proteins and Akt Signaling. The drugs Pirfenidone and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotypes are homeostasis/metabolism and growth/size/body region

Disease Ontology : 12 A lower respiratory tract disease in which the function of the lungs is adversely affected by narrowing or blockage of the airways resulting in poor air flow, a loss of elasticity in the lungs that produces a decrease in the total volume of air that the lungs are able to hold, and clotting, scarring, or inflammation of the blood vessels that affect the ability of the lungs to take up oxygen and to release carbon dioxide.

Sources

Related Diseases for Lung Disease

About this section

Diseases related to Lung Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 645)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 34.3 ABCA3 CXCL8 IFIH1 IL10 IL1B ITGA3
2 pulmonary disease, chronic obstructive 33.4 CFTR CXCL8 ELANE SERPINA1 SFTPB SFTPD
3 desquamative interstitial pneumonia 33.1 ABCA3 MUC5B SFTPC
4 pneumoconiosis 33.0 CXCL8 IL1B MUC5B SERPINA1 TNF
5 alpha-1-antitrypsin deficiency 32.9 CXCL8 ELANE SERPINA1
6 cystic fibrosis 32.9 CFTR CXCL8 ELANE SERPINA1 SFTPD
7 extrinsic allergic alveolitis 32.8 CXCL8 IL10 IL1B SFTPD
8 surfactant dysfunction 32.8 ABCA3 SFTPA1 SFTPB SFTPC
9 silicosis 32.8 CXCL8 IL1B SFTPD TNF
10 pulmonary fibrosis 32.7 IL1B MUC5B SFTPA1 SFTPA2 SFTPC SFTPD
11 bronchopulmonary dysplasia 32.7 CXCL8 ELANE SFTPB
12 bagassosis 32.6 CXCL8 IL1B
13 aspergillosis 32.6 CFTR ELANE IL10 SFTPA2 SFTPD TNF
14 respiratory failure 32.5 CXCL8 ELANE SERPINA1 SFTPB SFTPC SFTPD
15 bronchiolitis 32.5 CXCL8 IL10 MUC5B TNF
16 asthma 32.5 CFTR CXCL8 ELANE IL10 IL1B TNF
17 pulmonary fibrosis, idiopathic 32.5 ABCA3 CXCL8 ELANE IL1B MUC5B SFTPA1
18 allergic bronchopulmonary aspergillosis 32.4 CFTR SFTPA2 SFTPD
19 pulmonary alveolar proteinosis 32.4 SFTPB SFTPC SFTPD
20 respiratory distress syndrome in premature infants 32.4 ABCA3 SFTPA1 SFTPB SFTPC
21 bronchiolitis obliterans 32.4 CXCL8 IL10 TNF
22 idiopathic interstitial pneumonia 32.3 CXCL8 ELANE MUC5B SFTPA1 SFTPA2 SFTPC
23 pneumonia 32.2 CXCL8 ELANE IL10 IL1B MUC5B SFTPB
24 arthritis 31.6 CXCL8 IL10 IL1B TNF
25 bronchiectasis 31.3 CFTR CXCL8 ELANE SERPINA1
26 mycobacterium abscessus 31.2 CFTR CXCL8 SERPINA1 TNF
27 bronchitis 31.0 CFTR CXCL8 ELANE SERPINA1 TNF
28 colitis 30.8 CXCL8 IL10 IL1B TNF
29 sleep apnea 30.8 CXCL8 IL1B TNF
30 haemophilus influenzae 30.7 CXCL8 IL1B TNF
31 ulcerative colitis 30.7 CXCL8 IL10 IL1B TNF
32 acute respiratory distress syndrome 30.6 CXCL8 ELANE IL1B SFTPB SFTPC SFTPD
33 chorioamnionitis 30.6 CXCL8 ELANE IL1B TNF
34 pulmonary emphysema 30.4 ELANE SERPINA1 SFTPC SFTPD
35 bacterial pneumonia 30.4 CXCL8 ELANE SFTPB SFTPD
36 vasculitis 30.4 ELANE SERPINA1 TNF
37 acquired immunodeficiency syndrome 30.4 IL10 IL1B TNF
38 pulmonary edema 30.2 CFTR CXCL8 IL10 IL1B TNF
39 rheumatic disease 30.2 IL10 IL1B TNF
40 chronic mucocutaneous candidiasis 30.2 IL10 IL1B TNF
41 cytomegalovirus infection 30.2 CXCL8 IL1B TNF
42 neonatal respiratory failure 30.2 ABCA3 SFTPB SFTPC
43 adult respiratory distress syndrome 30.2 CXCL8 ELANE IL10 SFTPB SFTPC TNF
44 inflammatory bowel disease 30.1 CXCL8 IL10 IL1B TNF
45 clonorchiasis 30.1 CXCL8 IL10 TNF
46 funisitis 30.1 CXCL8 IL10 IL1B
47 crohn's colitis 30.1 CXCL8 IL1B TNF
48 bacterial vaginosis 30.0 CXCL8 IL1B TNF
49 brucellosis 30.0 CXCL8 IL10 TNF
50 pertussis 30.0 IL10 IL1B TNF

Graphical network of the top 20 diseases related to Lung Disease:



Diseases related to Lung Disease
Sources

Symptoms & Phenotypes for Lung Disease

About this section

UMLS symptoms related to Lung Disease:


dyspnea, apnea, hemoptysis, snoring, coughing, labored breathing

MGI Mouse Phenotypes related to Lung Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 ABCA3 CFTR ELANE IFIH1 IL10 IL1B
2 growth/size/body region MP:0005378 10.18 CFTR IFIH1 IL10 IL1B ITGA3 MUC5B
3 hematopoietic system MP:0005397 10.11 CFTR ELANE IFIH1 IL10 IL1B MUC5B
4 mortality/aging MP:0010768 10.06 ABCA3 CFTR ELANE IFIH1 IL10 IL1B
5 immune system MP:0005387 10.03 CFTR ELANE IFIH1 IL10 IL1B ITGA3
6 neoplasm MP:0002006 9.61 ELANE IL10 IL1B ITGA3 SFTPC TERT
7 respiratory system MP:0005388 9.4 ABCA3 CFTR IL10 ITGA3 MUC5B SFTPA1
Sources

Drugs & Therapeutics for Lung Disease

About this section

Drugs for Lung Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1309)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pirfenidone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53179-13-8 40632
2
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51333-22-3 63006 5281004
3 Beractant Approved Phase 4,Phase 2,Not Applicable 108778-82-1
4
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68-04-2
5
Bosentan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147536-97-8 104865
6
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83905-01-5 55185 447043
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
8
Caspofungin Approved Phase 4,Phase 2,Phase 1,Not Applicable 179463-17-3, 162808-62-0 2826718 468682
9
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90566-53-3 62924
10
Iloprost Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 78919-13-8 6443959
11
Terbutaline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23031-25-6 5403
12
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53-03-2 5865
13
Metoprolol Approved, Investigational Phase 4,Phase 3,Not Applicable 37350-58-6, 51384-51-1 4171
14
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
15
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
16
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10102-43-9 145068
17
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6, 15438-31-0 23925 27284
18
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 564-25-0 54671203
19
Simvastatin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 79902-63-9 54454
20
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 69-65-8 453 6251
21
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
22
Sultamicillin Approved, Investigational Phase 4,Phase 3 76497-13-7
23
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 302-25-0
24
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 2921-57-5
25
Ampicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 69-53-4 6249
26
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
27
Sulbactam Approved Phase 4,Phase 3,Phase 1,Phase 2 68373-14-8
28
Ipratropium Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60205-81-4, 22254-24-6 43232 657309
29
Procaterol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 72332-33-3 688561
30
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
31
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
32
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2 54-85-3 3767
33
Rifampicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13292-46-1 5381226 5458213
34
Pyrazinamide Approved, Investigational Phase 4,Phase 3,Phase 2 98-96-4 1046
35
Metformin Approved Phase 4,Phase 2,Early Phase 1 657-24-9 14219 4091
36
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 171596-29-5 110635
37
Epoprostenol Approved Phase 4,Phase 3,Phase 2 35121-78-9, 61849-14-7 5280427 5282411
38
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772
39
Dalteparin Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 9005-49-6
40
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6 772 46507594
41
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
42
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
43
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 1,Not Applicable 59467-70-8 4192
44
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 113775-47-6 68602 5311068
45
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 354812-41-2, 151096-09-2 152946
46
Penicillin G Approved, Vet_approved Phase 4,Phase 3 61-33-6 5904
47
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 85721-33-1 2764
48
Tazobactam Approved Phase 4,Phase 3,Phase 1,Not Applicable 89786-04-9 123630
49
Clarithromycin Approved Phase 4,Phase 3,Phase 2 81103-11-9 84029
50
Cefuroxime Approved Phase 4,Phase 2,Phase 3,Not Applicable 55268-75-2 5361202 5479529

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
2 Prevention of Chronic Lung Disease (CLD) in Preterm Infants Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
3 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
4 Prophylactic Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD) Unknown status NCT00132860 Phase 4 azithromycin
5 Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study Unknown status NCT00637065 Phase 4 Bosentan;Placebo
6 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
7 Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
8 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
9 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
10 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
11 Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
12 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01116063 Phase 4 Inhaled iloprost
13 Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease Unknown status NCT01465906 Phase 4 tulobuterol;Tiotropium Bromide;tiotropium bromide
14 The Role of Opinion Leaders in Enhancing Evidence-based Care After Chronic Obstructive Pulmonary Disease (COPD) Emergency Department (ED) Visits Unknown status NCT01107613 Phase 4
15 Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00288548 Phase 4 Metoprolol
16 Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
17 Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial Unknown status NCT00120978 Phase 4 Advair;Flovent
18 Inspiratory Muscle Training for Breathless Patients With Chronic Obstructive Pulmonary Disease and Heart Failure Unknown status NCT02579200 Phase 4
19 Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD Unknown status NCT02937974 Phase 4 Xuebijing;Placebo
20 Small Airways Evaluation and Treatment Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
21 Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
22 Pulmonary Gas Exchange Response to Indacaterol in COPD Unknown status NCT02547558 Phase 4 Indacaterol
23 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
24 Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
25 Simvastatin in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
26 Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD Unknown status NCT00860938 Phase 4 Budesonide
27 Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
28 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
29 Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD Unknown status NCT01892488 Phase 4 Sultamicillin;Placebo
30 LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure Unknown status NCT00668408 Phase 4
31 The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD Unknown status NCT01243788 Phase 4 Salmeterol/Fluticasone Propionate
32 Description of the Ability to Learn How to Handle Inhaler Devices in COPD Unknown status NCT02813200 Phase 4 Seretide® Diskus® 500/550 μg;Ultibro® Breezhaler® 110/50 μg;Spiriva® Respimat® 2,5 μg
33 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD Unknown status NCT02197871 Phase 4
34 Airway Effects of Tiotropium in Patients With COPD Unknown status NCT02683668 Phase 4
35 AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Unknown status NCT01460108 Phase 4
36 An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
37 Strategy to Improve Adherence of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
38 EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
39 Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
40 Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox Unknown status NCT02383797 Phase 4
41 Preterm Infant Inhaled Albuterol Dosing Unknown status NCT02447250 Phase 4 Varied albuterol dose response
42 Bronchiolitis All-study, SE-Norway Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
43 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
44 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
45 Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. Unknown status NCT00705588 Phase 4 Tadalafil;Vardenafil
46 Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism Unknown status NCT01956955 Phase 4 enoxaparin ,alteplase, unfractionated heparin
47 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Unknown status NCT00560287 Phase 4
48 Transfusion Strategies in Weaning Patients Unknown status NCT01256645 Phase 4
49 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
50 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4

Search NIH Clinical Center for Lung Disease

Cochrane evidence based reviews: lung diseases

Sources

Genetic Tests for Lung Disease

About this section

Genetic tests related to Lung Disease:

# Genetic test Affiliating Genes
1 Disorder of Lung 30
Sources

Anatomical Context for Lung Disease

About this section

MalaCards organs/tissues related to Lung Disease:

42
Lung, Testes, Heart, Neutrophil, Endothelial, Bone, Brain
Sources

Publications for Lung Disease

About this section

Articles related to Lung Disease:

(show top 50) (show all 7474)
# Title Authors Year
1
A Rare Case of Adenosquamous Carcinoma Arising in a Background of IgG4-Related Lung Disease: A case report. ( 30853707 )
2019
2
Adult-onset Still's disease-associated interstitial lung disease represents severe phenotype of the disease with higher rate of haemophagocytic syndrome and relapse. ( 30767871 )
2019
3
Caveolae, Caveolin-1 and Lung Diseases of Aging. ( 30686114 )
2019
4
Clinical characteristics and outcome in patients with antisynthetase syndrome associated interstitial lung disease: a retrospective cohort study. ( 30834073 )
2019
5
Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis. ( 30799358 )
2019
6
Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality. ( 30710005 )
2019
7
Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology. ( 30652645 )
2019
8
Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease. ( 30604628 )
2019
9
High levels of antibodies to citrullinated α-enolase peptide-1 (CEP-1) identify erosions and interstitial lung disease (ILD) in a Chinese rheumatoid arthritis cohort. ( 30611755 )
2019
10
Isolated Cystic Lung Disease: An Algorithmic Approach to Distinguishing Birt-Hogg-Dubé Syndrome, Lymphangioleiomyomatosis, and Lymphocytic Interstitial Pneumonia. ( 30888864 )
2019
11
Evaluation of bone disease in patients with cystic fibrosis and end-stage lung disease. ( 30843951 )
2019
12
Severe Restrictive Lung Disease in One of the Oldest Documented Males With Coffin-Lowry Syndrome. ( 30791716 )
2019
13
BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency. ( 30843876 )
2019
14
Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities. ( 30604506 )
2019
15
Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities. ( 30605544 )
2019
16
Approach to the Patient With Connective Tissue Disease and Diffuse Lung Disease. ( 30684993 )
2019
17
Feasibility of low-dose CT with spectral shaping and third-generation iterative reconstruction in evaluating interstitial lung diseases associated with connective tissue disease: an intra-individual comparison study. ( 30737567 )
2019
18
Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. ( 30764869 )
2019
19
Connective Tissue Disease Associated Interstitial Lung Disease - An Acute Exacerbation In Emergency Room. ( 30868797 )
2019
20
Adapting Proteostasis and Autophagy for Controlling the Pathogenesis of Cystic Fibrosis Lung Disease. ( 30774592 )
2019
21
Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation. ( 30813645 )
2019
22
Quantitative multivolume proton-MRI in patients with cystic fibrosis lung disease: comparison with clinical indicators. ( 30819810 )
2019
23
Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease. ( 30875857 )
2019
24
Posaconazole therapy in children with cystic fibrosis and Aspergillus-related lung disease. ( 30877757 )
2019
25
Targeting of Cathepsin S Reduces Cystic Fibrosis-like Lung Disease. ( 30655278 )
2019
26
Lung disease and vitamin D levels in cystic fibrosis infants and preschoolers. ( 30663283 )
2019
27
Single-breath washout and association with structural lung disease in children with cystic fibrosis. ( 30758143 )
2019
28
Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis. ( 30291871 )
2019
29
Juvenile dermatomyositis associated with anti-melanoma differentiation-associated gene 5 antibody positivity without complications of interstitial lung disease during the clinical course: A case report. ( 30869164 )
2019
30
Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis. ( 30888566 )
2019
31
Clinical value of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis. ( 30614031 )
2019
32
Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis. ( 30614890 )
2019
33
Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis. ( 30647164 )
2019
34
Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. ( 30739212 )
2019
35
Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature review. ( 30746580 )
2019
36
Serum matrix metalloproteinase levels in polymyositis/dermatomyositis patients with interstitial lung disease. ( 30851107 )
2019
37
Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial: reply. ( 30809671 )
2019
38
Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. ( 30809674 )
2019
39
Nivolumab-induced interstitial lung disease in a patient with gastric cancer. ( 30863551 )
2019
40
Lung disease in STAT3-Hyper-IgE-Syndrome requires intense therapy. ( 30793327 )
2019
41
EXPRESS: Hypoxia-induced Pulmonary Hypertension and Chronic Lung Disease: Caveolin-1 Dysfunction an Important Underlying Feature. ( 30806156 )
2019
42
Pulmonary hypertension in chronic lung disease and hypoxia. ( 30545980 )
2019
43
Impact of influenza on hospitalization rates in children with a range of chronic lung diseases. ( 30701672 )
2019
44
Telomeres in Interstitial Lung Disease: The Short and the Long of It. ( 30540921 )
2019
45
A review of filamin A mutations and associated interstitial lung disease. ( 30547349 )
2019
46
Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases. ( 30558827 )
2019
47
Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis. ( 30572131 )
2019
48
Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort. ( 30592376 )
2019
49
A quantitative method for measuring the changes of lung surface wave speed for assessing disease progression of interstitial lung disease. ( 30598191 )
2019
50
Interstitial Lung Disease in patients with Polymyalgia Rheumatica: A case series. ( 30603602 )
2019
Sources

Variations for Lung Disease

About this section
Sources

Expression for Lung Disease

About this section
Search GEO for disease gene expression data for Lung Disease.
Sources

Pathways for Lung Disease

About this section

Pathways related to Lung Disease according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Metabolism of proteins 67
Show member pathways
 13.68 ABCA3 CFTR CXCL8 IFIH1 MUC5B NSMCE3
2
Akt Signaling 65
Show member pathways
 13.35 CXCL8 IL10 IL1B ITGA3 TNF TSC1
3
Toll-like Receptor Signaling Pathway 38 1
Show member pathways
 13.11 CXCL8 IL10 IL1B SFTPA2 SFTPD TNF
4
Human cytomegalovirus infection 38
Show member pathways
 12.89 CXCL8 IFIH1 IL1B TNF TSC1 TSC2
5
IL-17 Family Signaling Pathways 66
Show member pathways
 12.24 CFTR CXCL8 IL1B MUC5B TNF
6
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.19 CXCL8 IL10 IL1B TERT TNF
7
IL-1 Family Signaling Pathways 66
Show member pathways
 12.14 CFTR CXCL8 IL1B MUC5B TNF
8
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.1 CXCL8 IL10 IL1B TNF
9
Bacterial infections in CF airways 23
Show member pathways
 12.02 CFTR CXCL8 IL1B SFTPA1 SFTPD TNF
10
Interleukin-4 and 13 signaling 67
11.91 CXCL8 IL10 IL1B TNF
11
AGE-RAGE signaling pathway in diabetic complications 38
11.84 CXCL8 IL1B TNF
12
Hematopoietic cell lineage 38
11.82 IL1B ITGA3 TNF
13
Amoebiasis 38
11.81 CXCL8 IL10 IL1B TNF
14
NF-kappa B signaling pathway 38
11.8 CXCL8 IL1B TNF
15
Rheumatoid arthritis 38
11.78 CXCL8 IL1B TNF
16
Diseases of metabolism 67
Show member pathways
 11.73 SFTPA1 SFTPA2 SFTPB SFTPC SFTPD
17
Innate Lymphoid Cell Differentiation Pathways 66
11.72 IL10 IL1B TNF
18
Dendritic Cells Developmental Lineage Pathway 66
11.68 IL10 IL1B TNF
19
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.66 IL10 IL1B TNF
20